UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Current pharmacological treatment of idiopathic inflammatory myopathies

Fasano, S; Alves, SC; Isenberg, DA; (2016) Current pharmacological treatment of idiopathic inflammatory myopathies. Expert Review of Clinical Pharmacology , 9 (4) pp. 547-558. 10.1586/17512433.2016.1136561. Green open access

[thumbnail of Fasano_Current pharmacological treatment of idiopathic inflammatory myopathies.pdf]
Preview
Text
Fasano_Current pharmacological treatment of idiopathic inflammatory myopathies.pdf - Accepted Version

Download (253kB) | Preview

Abstract

The idiopathic inflammatory myopathies are uncommon and heterogeneous disorders. Their classification is based on distinct clinicopathologic features. Although idiopathic inflammatory myopathies share some similarities, different subtypes may have variable responses to therapy, so it is very important to distinguish the correct subtype. There are few randomised, double blind placebo controlled studies to support the current treatment. High dose corticosteroids continue to be the first-line therapy and other immunosupressive drugs are used in refractory cases, as well as steroid-sparing agents. Some novel therapeutic approaches have emerged as potential treatment including tacrolimus, intravenous immunoglobulin and rituximab, following good outcomes reported in case studies. However, more randomised controlled trials are needed. This review considers the current and the potential future therapies for inflammatory myopathies.

Type: Article
Title: Current pharmacological treatment of idiopathic inflammatory myopathies
Open access status: An open access version is available from UCL Discovery
DOI: 10.1586/17512433.2016.1136561
Publisher version: http://dx.doi.org/10.1586/17512433.2016.1136561
Language: English
Additional information: Copyright © 2016 Taylor & Francis. This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Review of Clinical Pharmacology, on 6 February 2016, available online: http://dx.doi.org/10.1586/17512433.2016.1136561
Keywords: Science & Technology, Life Sciences & Biomedicine, Pharmacology & Pharmacy, Idiopathic inflammatory myopathy, inclusion body myositis, treatment, dermatomyositis, polymyositis, Inclusion-body Myositis, Stem-cell Transplantation, Interstitial Lung-disease, Alpha Monoclonal-antibody, Necrosis-factor-alpha, Of-the-literature, Juvenile Dermatomyositis, Intravenous Immunoglobulin, Refractory Polymyositis, Double-blind
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation
URI: https://discovery.ucl.ac.uk/id/eprint/1536416
Downloads since deposit
205Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item